Under construction – not a live service
Sign in
Taking people in TaiwanNo phase

Tests a robotic gait trainer with active assistance in chronic stroke survivors

Tests a walking robot in adults with chronic stroke, comparing active and passive assistance modes.

Plain-language title generated from the registry record
Registry title: The Feasibility and Therapeutic Effect of Hybrid End-effector Robot-assisted Gait Training With an Active-assisted Module in Chronic Stroke Survivors

Key facts

Where
Taipei, TaiwanSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Source: NCT07034521, who can take part

Where in Taiwan

  • National Taiwan University HospitalTaipei, TaiwanTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
National Taiwan University Hospital
Trial code
NCT07034521
Record updated
19 May 2026
Original description
Walking rehabilitation after stroke is most effective during the first three months of recovery, but even in the chronic phase-beyond six months post-stroke-a significant number of patients still show potential for gait improvement. Robot-assisted rehabilitation is becoming increasingly common in clinical settings, with various design modes available. However, the effectiveness of new products in improving gait or motor function still requires further investigation.Read full original descriptionShow less

The Feasibility and Therapeutic Effect of Hybrid End-effector Robot-assisted Gait Training With an Active-assisted Module in Chronic Stroke Survivors

Walking rehabilitation after stroke is most effective during the first three months of recovery, but even in the chronic phase-beyond six months post-stroke-a significant number of patients still show potential for gait improvement. Robot-assisted rehabilitation is becoming increasingly common in clinical settings, with various design modes available. However, the effectiveness of new products in improving gait or motor function still requires further investigation.

This study aims to evaluate the usability and therapeutic effects of a new end-effector exoskeleton robot system, HIWIN MRG-P110, for gait training in chronic stroke patients. The system uses foot pedal mechanisms to drive hip and knee movements for lower-limb training. Unlike its predecessor, this device allows adjustment of the active assistance ratio, encouraging users to engage in voluntary movement. It is designed for gait training in stroke patients and others with neurological impairments, but the usability and efficacy of this new training model remain to be verified.

This clinical trial is a randomized, single-blind, prospective study enrolling 60 stroke patients who are 6 months to 3 years post-onset and have a Functional Ambulation Category (FAC) level of 0 to 3. The study will explore how patients with varying degrees of motor weakness learn to adapt to the "active-assistive mode" in terms of speed and perception. Participants will be randomly assigned to either the active-assistive mode group or the fully passive mode group. Both groups will receive 15 treatment sessions over 5 weeks.

The study will compare the two groups in terms of:

1. Improvements in gait and balance immediately post-treatment and at 3-month follow-up 2. Changes in brain activity, as measured by functional near-infrared spectroscopy (fNIRS)

Inclusion: Aged between 18 and 80 years old; First-ever stroke, confirmed by brain CT or MRI, with onset between 6 months and 3 years prior to enrollment; Walking ability classified as Functional Ambulation Category (FAC) level 1 to level 3; Prior to the current stroke, the participant was an independent community ambulator without mobility impairments.

Exclusion: Lower limb musculoskeletal conditions causing wounds, pain, inability to bear weight, or significant leg length discrepancy (>2 cm after orthotic correction); Known history of osteoporotic fractures in the thoracolumbar spine or hip joints; Acute infections or unstable vital signs; Terminal illness with life expectancy less than six months; Presence of lower limb joint contractures, deformities, or severe spasticity (Modified Ashworth Scale score of 4); Inability to use the exoskeleton device due to body size, including:; Body weight > 135 kg; Thigh length < 36 cm or > 48 cm; Calf length < 42 cm or > 58 cm; Cognitive or communication impairments that prevent understanding of study instructions or completion of questionnaires; Significant orthostatic hypotension or inability to maintain upright posture for more than 30 minutes; Use of indwelling urinary catheter or tracheostomy; Pregnant women; Inability to attend 15 rehabilitation sessions and follow-up assessment at 3 months.

ClinicalTrials.gov NCT07034521